Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6889
US 7,459,534 Inactivation Resistant Factor VIII
US 11/455,116 Inactivation Resistant Factor VIII
US 12/252,024 Method of Producing Factor VIII Proteins by Recombinant Methods
US 12/758,457 Method of Producing Factor VIII Proteins by Recombinant Methods
US 13/015,043 Inactivation Resistant Factor VIII
IPSCIO Record ID: 201028
Elocta is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein.
IPSCIO Record ID: 185232
IPSCIO Record ID: 237378
The Licensor of England grants to the Licensee the following License
(i) a non-exclusive sub-license under United States Patent 4,994,371 to manufacture or have made for it Products and to use, sell or otherwise dispose of, anywhere in the world, Products made in the United States; and,
(ii) a non-exclusive license under the other Patents to manufacture or have made for it Products and to use, sell or otherwise dispose of, anywhere in the world, Products made in the countries covered by the aforesaid other Patents.
IPSCIO Record ID: 328345
Licensor grants an exclusive license, or in the case of licensed Third Party Patent Rights or Know-How, when permissible, an exclusive sublicense, in the Territory under Licensors Patent Rights, including Licensors rights in any jointly-owned Patent Rights, and Licensors Know How, to conduct the Collaborative Program and to make, use, sell, offer for sale, import, and have made, used, sold, and imported Products for use in the Hemophilia A Field and to each Additional Field(s) upon Licensees exercise of its option(s).
For the License Grant to Licensee Outside the Field(s), for sole inventions and knowhow made by Licensor during the term of and under the Research Program, which are Improvements in the coding and/or non-coding elements for optimizing and/or regulation of gene expression, Licensor grants a world-wide, non-exclusive,
including the right to grant sublicenses, to practice, make, use, sell, import and have practiced, made, used, sold and imported such Improvements for use outside the Field(s).
Alternate Ligand-Targeted Complex shall mean a molecular complex comprising a recombinant AsOR ligand or a non-plasma derived ligand such as, but not limited to, a synthetic carbohydrate ligand, said ligand having the ability to bind to the AsOR receptor and which is covalently linked to a polycation and noncovalently bound to DNA.
AsOR shall mean asialoorosomucoid.
Gene shall mean any one of the Factor VIII Gene or the Additional Gene(s), if any. Factor VIII Gene shall mean cDNA for full-length human factor VIII or an engineered deletion or substitution constructs, including B-domain deleted constructs, hereinafter modified, of human factor VIII.
Additional Gene shall mean full length or truncated cDNA for a specific human blood coagulation factor, other than factor VIII, which the parties mutually agree to add to the Collaborative Program and the Agreement.
Field shall mean any one of the Hemophilia A Field or the Additional Field(s), if any; or shall mean, collectively, the Hemophilia A Field and the Additional Field(s).
Additional Field shall mean, the treatment of any blood coagulation disorder in humans using Gene Delivery technology for targeting one or more Additional Gene into a mammalian cell of a patient.
IPSCIO Record ID: 127805
The licensed products mean viral vector products, including without limitation adenovirus (AV) and adeno-associated virus (AAV) viral vector products, for in vivo human gene therapy. Specifically excluded are utilization of non-viral vector products, any ex vivo approach based on the administration of living cells, Factor IX protein produced by or from transgenic animals, and any license rights to make, use, offer for sale, sell, or import Factor IX protein.